Moderna Advances Ebola Vaccine Into Human Testing
Moderna starts Phase 1 trials for Ebola vaccine mRNA-1469. See premarket MRNA stock reaction, analyst updates, and ETF exposure.
Moderna is testing a new Ebola vaccine on people for the first time, which shows the company is working on important health solutions. When a company starts testing new medicines, it's a sign they're investing in their future—though it takes years to know if it will work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.